Customer-mix repricing is the competitor vulnerability lens. PharmaDB joins company_buyer_concentration to company_trade_exports_by_molecule, surfaces buyer HHI and top-buyer share, and tags entry-window candidates. Refresh cadence is weekly.
Surface exporters with dangerously concentrated buyer bases. The customer-mix vulnerability map for any competitor or partner in the trade graph.
Of the four active ticagrelor exporters with declared trade in 2024, MSN Life Sciences holds the highest buyer HHI at 1,557 with top-buyer share of 38.9%. The structural read is moderate concentration with workable diversification. Across the broader warehouse, exporters like Niya Healthcare carry buyer HHI of 8,575 with 92.5% on the top buyer; one lost tender flips them into a pricing crisis. The brief surfaces both: in-portfolio competitive vulnerability, and the wider warehouse map of single-buyer-dependent exporters as entry-window candidates.
| # | Exporter | Country | Buyer HHI | Top buyer share | Export value (24mo) |
|---|---|---|---|---|---|
| 1 | Niya Healthcare | IN | 8575 buyer HHI | 92.5% top buyer | NAI |
| 2 | AMN Life Science | IN | 8652 buyer HHI | 92.9% top buyer | NAI |
| 3 | Shreya Life Sciences | IN | 9211 buyer HHI | 95.9% top buyer | NAI |
| 4 | Chandra Bhagat Pharma | IN | 9802 buyer HHI | 99.0% top buyer | VAI |
| 5 | Graviti Pharms | US | 9614 buyer HHI | 98.0% top buyer | NAI |
Type the molecule INN to surface its exporter base, or type a supplier name to surface their buyer concentration. Default window is the last full year.
Buyer HHI, distinct buyer count, and top-buyer share per supplier. Suppliers with HHI above 4,000 or top-buyer share above 70% are surfaced with a vulnerability chip.
Citation-anchored brief: the vulnerable suppliers, the dependency magnitude, and the recommended posture (entry window vs renegotiation signal vs leave-alone).
Suppliers with concentrated buyer bases are one lost tender from a pricing crisis. The HHI surface flags the vulnerability before the lost-tender event hits the trade flow.
When a single-buyer-dependent competitor loses the buyer, the lane opens. The brief flags candidates and surfaces the historical lane HHI so the user can size the entry opportunity.
On contract renewal with a buyer who runs concentrated suppliers, the repricing leverage is asymmetric. The brief surfaces buyer-side dependencies so the user can negotiate accordingly.
Buyer concentration aggregates refresh weekly. The vulnerability map reruns on every refresh; the brief carries the exact computation timestamp.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Ten exporters · 2024 buyer HHI on the 0-10,000 scale · single-buyer dependency triggers a vulnerability chip.
Customer-mix repricing is the competitor vulnerability lens. PharmaDB joins company_buyer_concentration to company_trade_exports_by_molecule, surfaces buyer HHI and top-buyer share, and tags entry-window candidates. Refresh cadence is weekly.
A supplier with one buyer at 90%+ share has no repricing power. When that buyer re-tenders, the supplier either accepts the new (usually lower) price or loses the volume. The HHI surfaces structural vulnerability before the lost-tender event.
Above 4,000 (on the 0-10,000 scale) signals meaningful concentration. Above 7,000 signals structural vulnerability. Above 9,000 means one buyer is effectively the entire business; one negative outcome flips the supplier.
When a concentration-vulnerable competitor loses their anchor buyer, the lane opens for another supplier. The brief flags candidates so the user's sales team can approach the buyer with a pricing proposal at the moment of vulnerability.
Mirror analysis. The user uploads their own export list (optional) and the brief surfaces their internal HHI. Concentrated own-side means the user is the vulnerable supplier; pricing power is limited until customer diversification.
Aggregate counts and HHI are surfaced; named buyers are not exposed in the brief. The trade-data disclaimer threshold is respected at the query layer. The vulnerability signal is the dependency magnitude, not the named counterparty.
Buyer concentration aggregates refresh weekly. The vulnerability map reruns on every refresh; the catalog row carries the exact timestamp.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.